NeuroPace (NPCE) Profit After Tax Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 18.66% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 13.84% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | -27.98% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 14.60% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 71.04% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 12.92% |
| 10 | NeuroPace | 463.82 Mn | 412.12 Mn | 18.91 Mn | 38.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.10% |
| Mar 31, 2026 | -1.52% |
| Dec 31, 2025 | 48.02% |
| Sep 30, 2025 | 35.88% |
| Jun 30, 2025 | -15.13% |
| Mar 31, 2025 | 26.17% |
| Dec 31, 2024 | 15.32% |
| Sep 30, 2024 | 24.87% |
| Jun 30, 2024 | 17.65% |
| Mar 31, 2024 | 13.98% |
| Dec 31, 2023 | 38.52% |
| Sep 30, 2023 | 37.80% |
| Jun 30, 2023 | 28.10% |
| Mar 31, 2023 | 9.48% |
| Dec 31, 2022 | 5.70% |
| Sep 30, 2022 | -44.75% |
| Jun 30, 2022 | -49.40% |
| Mar 31, 2022 | -30.09% |
| Dec 31, 2021 | -133.17% |
| Sep 30, 2021 | -95.56% |